bladder tumor recurrence

PreclinicalBiologic

UUniversity Hospital, Rouen

bladder tumor recurrence is one of 21 biologic programs targeting Bladder Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bladder TumorActive, not recruiting

Bladder TumorPreclinical

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Bladder Tumor

#DrugCompanyPhaseTrials

Balversa

Nolvadex

Gemzar

Adrucil

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—6

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Mitosol

Opdivo

Beyfortus

Keytruda

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bladder Tumor1 trial

URO-BCG-4 : Bladder Tumors Immunotherapy

Completed·UUniversity Hospital, Rouen··NCT00213655·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for bladder tumor recurrence. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bladder tumor recurrence compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bladder tumor recurrence. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Rouen

bladder tumor recurrence

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bladder Tumor1 trial

References

Drug Info

Quick Facts

Related News